AKTS

17.37

1.76% 0.30

Dopo l'orario di chiusura: 17.13 -0.24 -1.38%

Aktis Oncology Inc (AKTS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$17.07

Aprire:

$16.71

Volume 24 ore:

384.69K

Relative Volume:

0.11

Capitalizzazione di mercato:

$958.30M

Reddito:

$29.71M

Utile/perdita netta:

$-69.15M

Rapporto P/E:

-33.86

EPS:

-0.513

Flusso di cassa netto:

$-52.28M

1 W Prestazione:

-1.42%

1M Prestazione:

-13.15%

6M Prestazione:

+46,594%

1 anno Prestazione:

+46,594%

Intervallo 1D:

$16.25

$17.47

Intervallo di 1 settimana:

$14.72

$19.36

Portata 52W:

$14.72

$29.16

Aktis Oncology Inc Stock (AKTS) Company Profile

Nome

Aktis Oncology Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

978-237-4380

Indirizzo

17 DRYDOCK AVENUE, BOSTON, NC

Dipendente

Cinguettio

@akoustisinc

Prossima data di guadagno

2024-12-11

Ultimi documenti SEC

AKTS's Discussions on Twitter

Compare AKTS vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKTS Aktis Oncology Inc	17.37	958.30M	29.71M	-69.15M	-52.28M	-0.513
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-09	Iniziato	H.C. Wainwright	Buy
2026-02-03	Iniziato	BofA Securities	Buy
2026-02-03	Iniziato	JP Morgan	Overweight
2026-02-03	Iniziato	Leerink Partners	Outperform
2026-02-03	Iniziato	TD Cowen	Buy
2024-01-04	Downgrade	Piper Sandler	Overweight → Neutral
2023-09-06	Downgrade	B. Riley Securities	Buy → Neutral
2023-01-24	Iniziato	B. Riley Securities	Buy
2021-02-02	Reiterato	Craig Hallum	Buy
2021-01-15	Reiterato	Craig Hallum	Buy
2019-09-18	Downgrade	Northland Capital	Outperform → Market Perform
2019-07-10	Aggiornamento	Northland Capital	Market Perform → Outperform
2019-05-13	Reiterato	Craig Hallum	Buy
2019-02-05	Reiterato	Craig Hallum	Buy
2019-02-05	Downgrade	Northland Capital	Outperform → Market Perform
2018-12-18	Iniziato	Craig Hallum	Buy
2018-11-30	Iniziato	Lake Street	Buy
2018-06-22	Iniziato	Loop Capital	Buy
2018-02-09	Iniziato	Drexel Hamilton	Buy

Mostra tutto

Aktis Oncology Inc Borsa (AKTS) Ultime notizie

Mar 31, 2026

Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks

Mar 31, 2026

Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat

Mar 31, 2026

Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech

Mar 31, 2026

H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada

Mar 31, 2026

AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus

Mar 31, 2026

FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia

Mar 31, 2026

Mar 30, 2026

Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan

Mar 30, 2026

AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView

Mar 30, 2026

Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan

Mar 30, 2026

Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

Mar 30, 2026

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com

Mar 30, 2026

FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com

Mar 30, 2026

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - The Manila Times

Mar 30, 2026

Aktis Oncology Announces FDA Clearance of Investigational - GlobeNewswire

Mar 30, 2026

IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace

Mar 30, 2026

This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN

Mar 30, 2026

Mar 28, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Value Benchmark - marketscreener.com

Mar 19, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell Small Cap Comp Value Benchmark - MarketScreener

Mar 19, 2026

Mar 17, 2026

Huge insider buying now at this insurance giant and 2 biotechs - msn.com

Mar 17, 2026

Mar 14, 2026

Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 14, 2026

Mar 11, 2026

Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals

Mar 11, 2026

Mar 10, 2026

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail

Mar 10, 2026

Mar 09, 2026

AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView

Mar 09, 2026

AKTS: Innovative radiopharmaceutical platform targets major cancer types, backed by strong pipeline and funding - TradingView

Mar 09, 2026

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 09, 2026

Mar 08, 2026

Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm

Mar 08, 2026

Mar 06, 2026

Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm

Mar 06, 2026

Mar 05, 2026